^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

Excerpt:
The four subtypes differed significantly in progression-free survival (P = 8.88×10−6) and overall survival (P = 1.70×10−4), with the BN2 and EZB subtypes having much more favorable outcomes than the MCD and N1 subtypes (Fig. 4A ​and 4B). The predicted 5-year overall survival rates for the MCD, N1, BN2, and EZB subtypes were 26%, 36%, 65%, and 68%, respectively.
DOI:
10.1056/NEJMoa1801445